Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma
Journal of Oncology Pharmacy Practice · 2026
DOI: 10.1177/10781552241281900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2026. Verfasst von Michio Kimura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan. Hauptthemen laut MEDLINE: Fatigue, Carcinoma, Hepatocellular, Liver Neoplasms, Gastrointestinal Diseases. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Lenvatinib (LEN) is the standard treatment for hepatocellular carcinoma (HCC). In clinical practice, gastrointestinal (GI) symptoms such as fatigue and loss of appetite often lead to dose reduction or treatment discontinuation. This study aimed to identify the predictors of patients who will experience dose reduction or treatment discontinuation owing to fatigue or GI symptoms during LEN treatment for HCC.
Methods
We retrospectively identified 99 patients who received LEN at the Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and December 2023. To investigate the risk factors for treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration, patients were divided into two groups based on whether treatment discontinuation or dose reduction occurred due to fatigue or GI symptoms during LEN administration (37 patients) or not (62 patients). We compared baseline characteristics between the two groups.
Results
Multivariate analysis revealed that body weight (odds ratio 4.310, 95% confidence interval 1.380–13.500; P = 0.002) was an independent risk factor that significantly contributed to treatment discontinuation or dose reduction owing to fatigue or GI symptoms during LEN administration. The cut-off value calculated using the body weight curve was 55.0 kg. Using this cutoff value, the sensitivity and specificity of body weight to detect treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration were 83.9% and 56.8%, respectively.
Conclusion
In clinical practice, patients weighing less than 55 kg who start with a full dose will likely experience weight loss or discontinuation during treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
ORCID-Profile: Michio Kimura, Eiseki Usami
Zitieren
APA
Kimura, M., Yamada, S., Go, M., Yasuda, S., Toyoda, H., & Usami, E. (2026). Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241281900
Vancouver
Kimura M, Yamada S, Go M, Yasuda S, Toyoda H, Usami E. Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma. Journal of Oncology Pharmacy Practice. 2026. doi:10.1177/10781552241281900
BibTeX
@article{Kimura2026,
author = {Kimura, Michio and Yamada, Shiori and Go, Makiko and Yasuda, Satoshi and Toyoda, Hidenori and Usami, Eiseki},
title = {Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma},
journal = {Journal of Oncology Pharmacy Practice},
year = {2026},
doi = {10.1177/10781552241281900}
}
EUVIMED